Lifecome Biochemistry Co Ltd (002868) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Lifecome Biochemistry Co Ltd ¥4.36, price ¥22.30, upside -80.5%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Lifecome Biochemistry Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥9.08 – ¥61.57 · fair‑value band ¥2.35 – ¥6.81 · the ¥22.30 price screens above the ¥4.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Lifecome Biochemistry Co in your weekly email
Every Wednesday you see whether Lifecome Biochemistry Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.
Stock analysis
Lifecome Biochemistry Co Ltd (002868) currently trades at ¥22.30, while our model-based Fair Value estimate is ¥4.36, 80.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: ¥2.35 (bear) to ¥6.81 (bull), the price of ¥22.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Lifecome Biochemistry Co Ltd reported revenue of 517M CNY in FY2025 versus 363M CNY in FY2021, a compound +9.2%/yr. Reported net income was −139M CNY in FY2025.
Key figures
Market cap 4.1B CNY (≈ $613M) · P/S ratio 8.16 · EPS (TTM) ¥−0.6700 · Dividend yield 1.0% · Net margin −27.0% · Return on equity −1,189% · Return on assets (EBIT) −14.3% · Operating margin 17.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (medium confidence).
What moves the price
The share trades about 52% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, 002868 screens richer than that median.
Fair Value models
Bear ¥2.35Fair Value ¥4.36Bull ¥6.81
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−20.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Start year 2020 (pandemic). Over 10 years: +3.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.6% (2020) → −24.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Lifecome Biochemistry Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−80.4% · Bottom 25%
Profitability
Return on assets−2.8% · Above median
Net margin (TTM)−20.6% · Below median
Operating margin (TTM)17.1% · Top 25%
Growth and dividend
Revenue growth−9.6% · Below median
Dividend yield (TTM)1.0% · Below median
Balance sheet
Debt / equity0.48× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B9.69× · Priciest 25%
P/S (TTM)1.22× · Cheapest 25%
EV/EBITDA13.2× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)76· sector 97
DIVIDEND (yield)21· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Lifecome Biochemistry Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002868
Frequently asked questions
Is Lifecome Biochemistry Co Ltd (002868) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥4.36 versus a price of ¥22.30, about −80% upside (overvalued).
What is the fair value of 002868?
Our model-based fair value for Lifecome Biochemistry Co Ltd is ¥4.36 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥22.30.
What is the quality score of 002868?
Lifecome Biochemistry Co Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lifecome Biochemistry Co Ltd (002868)?
Our model-based price target is the fair value of ¥4.36 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario ¥2.35, optimistic scenario ¥6.81. It is a calculation from audited fundamentals, not an analyst target.
What is the Lifecome Biochemistry Co Ltd stock forecast for 2026?
Our models put fair value at ¥4.36, about −80% upside versus a price of ¥22.30 (overvalued). Cautious scenario ¥2.35, optimistic scenario ¥6.81. The calculation is refreshed regularly with new filings.
What is the revenue of Lifecome Biochemistry Co Ltd (002868)?
Lifecome Biochemistry Co Ltd reported trailing-twelve-month revenue of about 503M CNY (latest available figure, as of Sep 24, 2026).
Does Lifecome Biochemistry Co Ltd pay a dividend?
Lifecome Biochemistry Co Ltd currently shows a dividend yield of about 1.04% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Lifecome Biochemistry Co Ltd (002868)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lifecome Biochemistry Co Ltd it is ¥4.36 per share (as of Sep 24, 2026), against a price of ¥22.30. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Lifecome Biochemistry Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 002868 trades above its calculated fair value: price ¥22.30, fair value ¥4.36, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002868?
No. The price is what the market pays today (¥22.30); the fair value is what the company's own numbers justify (¥4.36). For Lifecome Biochemistry Co Ltd the two are ¥17.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lifecome Biochemistry Co Ltd worth?
The market values Lifecome Biochemistry Co Ltd at about 4.1B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥22.30; our models calculate a fair value of ¥4.36 per share.
What do the bullish and bearish scenarios say about 002868?
Our models span a range for Lifecome Biochemistry Co Ltd: cautious scenario ¥2.35, base ¥4.36, optimistic ¥6.81 per share (as of Sep 24, 2026, price ¥22.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lifecome Biochemistry Co Ltd (002868)?
Balance-sheet figures for Lifecome Biochemistry Co Ltd (as of Sep 24, 2026): debt of 0.48 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 002868 from its 52-week high?
Lifecome Biochemistry Co Ltd trades at ¥22.30, about 52% below its 52-week high of ¥46.40 and 5% above the low of ¥21.33 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.36 is for.
Which stocks are comparable to Lifecome Biochemistry Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lifecome Biochemistry Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥22.30, calculated fair value ¥4.36 (−80%), Quality Score 40/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002868 calculated?
We run Lifecome Biochemistry Co Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Lifecome Biochemistry Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lifecome Biochemistry Co Ltd (002868)?
The closing price on Sep 30, 2026 was ¥22.30. Our model-based fair value is ¥4.36, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lifecome Biochemistry Co Ltd right now?
The price sits above even our optimistic bull case (¥6.81). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥2.35 to ¥6.81). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Lifecome Biochemistry Co Ltd
How large is the market capitalisation of Lifecome Biochemistry Co Ltd (002868)?
The market capitalisation of Lifecome Biochemistry Co Ltd is 4.1B CNY (≈ $613M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lifecome Biochemistry Co Ltd (002868)?
The price-to-sales ratio of Lifecome Biochemistry Co Ltd is 8.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lifecome Biochemistry Co Ltd (002868)?
Earnings per share at Lifecome Biochemistry Co Ltd are ¥−0.6700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lifecome Biochemistry Co Ltd (002868)?
The dividend yield of Lifecome Biochemistry Co Ltd is 1.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lifecome Biochemistry Co Ltd (002868)?
The net margin of Lifecome Biochemistry Co Ltd is −27.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lifecome Biochemistry Co Ltd (002868)?
The return on equity (ROE) of Lifecome Biochemistry Co Ltd is −1,189% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lifecome Biochemistry Co Ltd (002868)?
On an EBIT basis the return on assets of Lifecome Biochemistry Co Ltd is −14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lifecome Biochemistry Co Ltd (002868)?
The operating margin of Lifecome Biochemistry Co Ltd is 17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lifecome Biochemistry Co Ltd (002868)?
Revenue at Lifecome Biochemistry Co Ltd is growing −9.6% versus a year earlier (3y avg +16.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lifecome Biochemistry Co Ltd (002868)?
Earnings per share at Lifecome Biochemistry Co Ltd are growing −76.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lifecome Biochemistry Co Ltd (002868) generate?
The free cash flow of Lifecome Biochemistry Co Ltd is −155M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lifecome Biochemistry Co Ltd (002868) carry?
The net debt of Lifecome Biochemistry Co Ltd is 131M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lifecome Biochemistry Co Ltd in the live analysis
One click puts Lifecome Biochemistry Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
